Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 02/26/25
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025GlobeNewsWire • 01/13/25
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of CatalystsBenzinga • 12/04/24
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of WorkforceBenzinga • 11/26/24
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business UpdateGlobeNewsWire • 11/25/24
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules CapitalGlobeNewsWire • 11/14/24
Alector Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/24
Alector Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/24
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)GlobeNewsWire • 07/28/24
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024GlobeNewsWire • 07/23/24
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology PlatformGlobeNewsWire • 06/10/24
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/27/24
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?Zacks Investment Research • 02/08/24
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's DiseaseGlobeNewsWire • 02/08/24